

OVARIAN TISSUE CRYOPRESERVATION (OTCP) ELIGIBILITY CRITERIA

Please note: This is a summary. Further details can be provided upon request.

1. Patient Demographics:

- Female patients aged between 12 months – 40 years who are not able to have egg/embryo storage and who are at significant/high risk of premature ovarian failure
- Prognosis – treatment intent - curative
- Cryopreservation procedure possible without unacceptable delay to definitive treatment i.e. within 7 days of referral
- Patient fit enough to undergo general anaesthetic and surgery

2. Treatment modalities:

The following treatments on their own or in combination place patients at significant/high risk of premature ovarian failure.

- Whole abdomen and pelvic radiation greater or equal to 15Gy in pre pubertal or 10Gy in post pubertal girls especially in combination with any alkylating agents
- Craniospinal radiation if the ovaries fall into the radiation field
- TBI as part of conditioning for bone marrow transplant
- Surgical removal of both ovaries
- Chemotherapy regimes containing cumulative doses of the following drugs:

Cyclophosphamide >5g/m ² (140mg/kg)	Melphalan 140 – 210 mg/m ²
Cisplatin >400mg/m ²	Busulphan 8 – 16mg/kg
Ifosfamide >60g/m ²	Thiotepa 600mg/m ²
	Procarbazine>4.2 g/m ²

If your patient does not meet the criteria, it may still be possible in exceptional circumstances, to refer them for OTCP after a discussion with lead OTCP or consultants at OUH.

Please contact sheila.lane@ouh.nhs.uk or Oxford Cell and Tissue Biobank on 01865 22 00 76.